A phase II study of cisplatin, ifosfamide and epirubicin combination chemotherapy in adults with nonmetastatic and extremity osteosarcomas

Oncology
Mert BasaranHaluk Onat

Abstract

Osteosarcoma is a rare malignancy, and patients with this disease benefit from adjuvant chemotherapy. While cisplatin, anthracyclines and ifosfamide are the most commonly used agents in the treatment of osteosarcoma, a search for the best combination with higher efficacy and minimal toxicity continues. We planned to evaluate the efficacy of epirubicin combined with cisplatin and ifosfamide in patients with localized primary osteosarcoma. Patients with nonmetastatic extremity osteosarcoma who were older than 15 years were included in the study. The preoperative chemotherapy regimen consisted of epirubicin 90 mg/m(2), cisplatin 100 mg/m(2) on day 1 and ifosfamide 2.0 g/m(2)/day with an equivalent dose of mesna on days 2-4, repeated every 21 days. Six cycles of this combination regimen were administered (3 cycles prior to surgery and 3 cycles postoperatively). Forty-five patients with localized osteosarcoma entered this phase II trial. Median follow-up was 64 months. Thirty-two patients (84%) received the assigned 6 cycles of chemotherapy. Complete and good histological response to neoadjuvant chemotherapy was 26 and 37%, respectively. The 5-year disease-free and overall survival rates were 41.9% (95% CI 33.6-50.2) and 48.2% (95% ...Continue Reading

References

Jan 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P A MeyersG Rosen
Sep 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D OrnadelJ Bridgewater
Jan 1, 1993·Cancer Treatment and Research·C B PrattI D Fleming
Dec 10, 1999·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P A VoûteS Weeden
Oct 5, 2001·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S FerrariG Bacci
Feb 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stefan S BielackKurt Winkler
Jun 5, 2002·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E I HaubenP C W Hogendoorn
Apr 17, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Allen M GoorinUNKNOWN Pediatric Oncology Group
Mar 19, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paul A MeyersHolcombe Grier
Oct 26, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stefano FerrariUNKNOWN Italian and Scandinavian Sarcoma Groups
Mar 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A Sérgio PetrilliUNKNOWN Brazilian Osteosarcoma Treatment Group Studies III and IV
Jan 24, 2007·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun

❮ Previous
Next ❯

Citations

Sep 8, 2009·Toxicology in Vitro : an International Journal Published in Association with BIBRA·Burhan KnouzyChristian Michoudet
Aug 1, 2009·Orthopaedic Surgery·Xiu-chun YuSong-feng Xu
Jul 23, 2011·International Journal of Cancer. Journal International Du Cancer·Daria BrambillaStefano Fais
Dec 19, 2014·Asian Pacific Journal of Cancer Prevention : APJCP·Yan-Yan LiYu-Bo Ma
May 1, 2012·Archives of Pathology & Laboratory Medicine·Nikhil A Sangle, Lester J Layfield
Sep 9, 2020·Clinical Kidney Journal·Gaël EnsergueixAlexandre Karras

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Imaging

Imaging techniques, including CT and MR, have become essential to tumor detection, diagnosis, and monitoring. Here is the latest research on cancer imaging.